GPT and pneumonitis: With regard to the safety profile, although there was no significant difference in the incidence of pneumonitis, increased AST or ALT, or nausea between lorlatinib and alectinib, regardless of the severity (any grade or Grade 3 or more), the incidence of not only G3-AEs but also AG-SAEs and AG-diarrhea was significantly more frequent in lorlatinib than in alectinib.